JBizNews Desk | May 6, 2026
Johnson & Johnson is moving forward with a closely watched inflammatory bowel disease therapy despite mixed results from two mid-stage clinical trials — a sign the healthcare giant believes the drug still has strong potential for patients with few remaining treatment options.
The company on Tuesday released Phase 2b data for JNJ-4804, an investigational co-antibody therapy designed to target both interleukin-23 and tumor necrosis factor-alpha, two key inflammatory pathways associated with Crohn’s disease and ulcerative colitis.
The results were presented at Digestive Disease Week 2026 in Chicago and focused on patients with moderately to severely active disease that had already proven resistant to multiple systemic therapies.
A New Approach to IBD Treatment
The studies — known as the DUET trials — evaluated a combination approach involving Johnson & Johnson’s existing drugs Tremfya and Simponi.
The goal was to determine whether simultaneously blocking two inflammatory mechanisms could deliver stronger and more durable remission rates than traditional single-drug treatments.
The program builds on earlier clinical data from 2022 that showed combination therapy could significantly improve remission rates in inflammatory bowel disease, helping spark broader industry interest in dual-target treatment strategies.
Inflammatory bowel disease, or IBD, includes Crohn’s disease and ulcerative colitis, chronic autoimmune disorders in which the immune system mistakenly attacks the digestive tract, often causing severe pain, inflammation, bleeding, and long-term complications.
What the Trials Showed
The topline results were mixed.
In Crohn’s disease patients, week-48 clinical remission rates reached 50.8% for patients receiving high-dose JNJ-4804, compared with 25.4% for golimumab alone and 42.5% for guselkumab alone.
Endoscopic response — a key measurement evaluating actual physical healing inside the digestive tract — reached 38.1% for JNJ-4804 compared with 19.8% and 33.9% for the individual therapies.
In ulcerative colitis patients, week-48 clinical remission rates came in at 41.0% for JNJ-4804 versus 11.5% for golimumab and 34.0% for guselkumab.
While those numbers outperformed the standalone therapies in several categories, the combined treatment failed to achieve statistically significant improvement across the broader patient population — missing the primary endpoint thresholds generally required for a clear trial success.
That outcome initially weighed on investor sentiment and raised questions about whether the drug would advance further in development.
Where the Strongest Signal Emerged
The more promising data came from a narrower but critically important group of patients: those who had already failed multiple prior treatments.
Among patients who had previously failed two or more systemic therapy classes, JNJ-4804 produced substantially stronger remission results.
In Crohn’s disease, remission rates nearly doubled compared with the strongest comparator treatment. In ulcerative colitis, remission rates were roughly 60% higher than the closest competing therapy.
That subgroup is considered one of the hardest-to-treat populations in gastrointestinal medicine, with many patients exhausting available biologic therapies over time.
“Currently in IBD treatment, each successive therapy produces diminishing returns, and patients who have failed multiple treatments have very limited options,” said Dr. Bruce E. Sands, Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine and lead author of the Crohn’s disease study.
“By combining two mechanisms of action, we’re seeing efficacy that appears to be additive — without increasing safety risk,” Sands said.
Safety Profile and Phase 3 Plans
Johnson & Johnson said the safety profile for JNJ-4804 was generally consistent with the safety of the two individual therapies when used separately.
Serious adverse events were relatively uncommon across both studies and were primarily gastrointestinal in nature.
Despite the mixed topline outcome, the company confirmed it plans to move the therapy into Phase 3 testing for both Crohn’s disease and ulcerative colitis.
The next-stage studies are expected to operate under the names DUET ENCORE-CD and DUET ENCORE-UC.
Johnson & Johnson describes JNJ-4804 as the first fixed-dose co-antibody therapy specifically designed to create “molecular synergy” in inflammatory bowel disease by simultaneously targeting both IL-23 and TNF pathways.
Why It Matters
For the estimated 3 million Americans living with Crohn’s disease or ulcerative colitis, treatment failures remain one of the biggest challenges in long-term care.
Many patients cycle through multiple biologic therapies over years with diminishing effectiveness, leaving them with limited alternatives once resistance develops.
By advancing JNJ-4804 into Phase 3 trials despite the mixed broader results, Johnson & Johnson is signaling confidence that dual-pathway therapies may still represent the next major frontier in IBD treatment — particularly for patients who have exhausted nearly every other option.
— JBizNews Desk
**© JBizNews.com. All rights reserved. This article is original reporting by JBizNews Desk. Unauthorized reproduction or redistribution is strictly prohibited.
